Though there is no official word, the sources said the government is not ready to give in to the indemnity demands of the US drug manufacturers against liabilities in case of adverse effects.
His visit to India followed a few cancelled plans since he took office in July 2019 due to the coronavirus pandemic crisis, with the two leaders holding several virtual talks and eventually meeting in person on the sidelines of the COP26 climate summit in Glasgow last November.
Sources close to the development said the company had no further supply commitments to the WHO, and therefore, there was no suspension of any upcoming orders, reports Sohini Das.
There is confusion over the United Kingdom government's vaccine recognition process for Indian travellers as even though Oxford/AstraZeneca Covishield, the India-manufactured Oxford/AstraZeneca COVID-19 vaccine, is on an updated international travel advisory, India is not yet on a list of 17 approved countries.
The SC said journalists' work can be done without coming in contact with people unlike lawyers and asked the Centre to consider the legal fraternity's request for priority in COVID-19 vaccination saying their livelihood depends on direct interaction with their clients.
The state also said that the police had recorded the statements of 400 witnesses so far and the investigators were in the process of finding the whereabouts of a doctor, who was an accused in the incident that took place at a housing society in suburban Kandivali, where one such camp was held.
Responding to a question on the Rajasthan government's claim that there is a shortage in COVID-19 vaccine stock, Union Health Secretary Rajesh Bhushan said the central government regularly monitors the availability of vaccine supply in all states and UTs and their consumption on a daily basis.
Poonawalla said the price will be around USD 5-6 per dose with an MRP of around Rs 1,000 for the two necessary doses.
An alert government in Delhi should have begun government-to-government discussions with Moscow the moment it came to know that Russians were developing a vaccine. That is to say, almost an year's time has been lost, observes Ambassador M K Bhadrakumar.
The sale of the Lincoln House in the Breach Candy area of south Mumbai, which used to house the US consulate, to the billionaire chairman of the Pune-based Serum Institute, makes it the largest real estate deal in the country's financial capital.
Bharat Biotech on Thursday said it plans to produce additional 200 million doses of COVID-19 vaccine 'Covaxin' at its subsidiary's Ankleshwar (Gujarat) based facility, taking the overall production volume of the vaccine to 1 billion (100 crore) dosages per annum.
Dr V K Paul, Member (Health) Niti Aayog, who also chairs the national expert group on COVID-19 vaccine administration, said the government attaches 'great importance to this offer of partnership from a very special friend to this nation'.
The production of Covaxin will increase from the current 10 million doses per month to 60 million-70 million by July-August.
They said 37.5 crore of Covishield doses from the Serum Institute of India and 28.5 crore Covaxin doses from Bharat Biotech will be procured by December.
In a report submitted Monday to Rajya Sabha chairman and Vice President M Venkaiah Naidu, the Parliamentary Standing Committee on Home Affairs also said there was a need for a comprehensive public health law to keep a tab on private hospitals and check black-marketing of medicines.
The UK government is under increasing pressure on Monday to review its COVID-19 vaccine protocol in place for travellers from India, after its updated rules effective from next month failed to recognise Indian vaccines under an expanded list of countries.
According to the World Health Organisation, 10 candidate vaccines for COVID-19 are in the clinical evaluation and 126 are in the pre-clinical stage.
The Central Drugs Standard Control Organisation has granted restricted emergency use authorisation to two new vaccines and a drug for COVID-19, taking the number of preventives and treatments available in India to 12.
Registering a steady increase for the 17th day in row, the active cases have increased to 4,52,647 comprising 3.80 per cent of the total infections, while the recovery rate has further dropped to 94.85 per cent, the data stated.
The Centre is looking to procure around 1 billion syringes between September and December to support the COVID-19 vaccination drive.
The Centre has shared a set of parameters with all states and UTs to enable service providers and monitoring teams under the national COVID-19 vaccination programme to identify any fake COVID-19 vaccines so that they are not administered in the country.
Procurement of coronavirus vaccines and raw materials to boost domestic production is set to be a major focus area of External Affairs Minister S Jaishankar's five-day visit to the United States beginning Monday.
The COVID-19 active caseload remained below two lakh for the 14th consecutive day.
'It was unfair to expect him to continue to keep on supplying vaccines without being given a firm commitment or a financial grant of any sort.'
The government may look at areas around Thonnakkal, in Thiruvananthapuram district, for the facility. If successful, this would be one of the few sites of Sputnik V owned by Russian firms outside that country. Shine Jacob and Sohini Das report.
Asked if the government has decided to administer the COVID-19 vaccine to the entire population free of cost on priority basis and if so, the target fixed to administer the doses, the health minister said according to Revised Guidelines for Implementation of National COVID Vaccination Program, which came into effect from June 21, all citizens aged 18 years and above, irrespective of their income status, are entitled to free vaccination at all government vaccination centres.
According to officials, an additional dose of vaccine is different from a booster dose.
The EC said that the data should be deleted by health authorities once the vaccination exercise concludes.
The number of people who have recuperated from the disease surged to 1,01,62,738 pushing the national COVID-19 recovery rate to 96.53 per cent.
India has received over USD 20 billion in FDI amid the coronavirus pandemic, Foreign Secretary Harsh Vardhan Shringla said on Tuesday, showcasing the country as one of the most attractive destinations for investment globally.
"The Indian Medical Association has requested all its 3.5 lakh members in 1,800 local branches to voluntarily come out to get vaccinated first to show the world that these vaccines are safe and efficacious," it said.
Those who have recovered from COVID-19 respond faster to the Covishield vaccine and reach high antibody levels, says a study, leading to hopes that they may not need a second dose and therefore help widen India's corona immunisation cover.
As per RDIF, Sputnik V has a number of key advantages, including that there are no strong allergies caused by Sputnik V.
The Netherlands has emerged as India's fifth-largest export destination in 2021-22 (FY22), jumping from its 10th position a year ago. Exports to the fifth-largest economy in the European Union (EU) bolted 94 per cent to $12.5 billion in the financial year ended March 31. In FY22, the Netherlands surpassed Hong Kong, Singapore, the UK, Germany, and Nepal to become India's largest export destination in the EU. Germany, which was earlier India's top European export destination (eighth position), has now dropped two ranks to 10th place.
The modalities of COVID-19 vaccine delivery, distribution and administration were discussed during the meeting.
'Pfizer India has submitted an application on December 4 to the DCGI seeking emergency use authorization for its COVID-19 vaccine in India'
The official expressed hope on the success of the five vaccines that are under different phases of trial in the country.
While the Indian government has been procuring Covid-19 vaccines at low prices so far, manufacturers have to declare the prices of vaccines they would supply to the open market (industries, private hospitals, etc) and state governments before May 1. Sohini Das reports.
The Indian vaccine industry largely feels there are two ways in which vaccine innovation can be spurred - one, get a high price for the product and two, have the government buy a few hundred million doses of the product at a certain price.
© 2026 Rediff.com - Investor Information - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances